Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant
IBER.U
IBER.U was delisted on the 1st of March, 2023.
27 hedge funds and large institutions have $49.6M invested in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $52.4M → $49.6M (-$2.81M)
21% less funds holding
Funds holding: 34 → 27 (-7)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OPU
Omni Partners US
Irvine,
California
|
+$186K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$10.4K |
| 3 |
Jane Street
New York
|
+$90 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Castle Creek Arbitrage
Avon,
Colorado
|
-$2.54M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.29M |
| 3 |
Millennium Management
New York
|
-$1.95M |
| 4 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$1.36M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.36M |
IBER.U Hedge Fund Activity: Q3 2021 in Review
27 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) for Q3 2021, worth a combined $49.6M — down 5.4% from $52.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IBER.U and 1 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Omni Partners US, adding an estimated $186K. The largest seller was Castle Creek Arbitrage, exiting entirely with an estimated $2.54M sold.
- 27 institutional investors held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) as of Q3 2021, down from 34 in Q2 2021.
- Funds reported $49.6M of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant stock for Q3 2021, down 5.4% quarter-over-quarter.
- 1 fund opened new Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant positions in Q3 2021 and 7 closed out, a net change of -6 holders.
- The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant buyer in Q3 2021 was Omni Partners US, an estimated $186K added.
- The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant seller in Q3 2021 was Castle Creek Arbitrage, an estimated $2.54M sold.
Based on aggregated 13F filings for Q3 2021.